Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for bioAffinity Technologies, Inc. (BIAF : NSDQ)

• Company Description    bioAffinity Technologies Inc. is a cancer diagnostics company which develops noninvasive, early-stage diagnostics to detect cancer and diseases of the lung and is researching targeted therapies to treat cancer. bioAffinity Technologies Inc. is based in SAN ANTONIO. Number of Employees: 57

• Price / Volume Information    Yesterday's Closing Price: $0.27 Daily Weekly Monthly 20 Day Moving Average: 421,699 shares Shares Outstanding: 28.47 (millions) Market Capitalization: $7.69 (millions) Beta: 2.52 52 Week High: $2.26 52 Week Low: $0.16 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 5.80% 3.94% 12 Week 7.53% -2.33% Year To Date -70.33% -74.99%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 3300 NACOGDOCHES ROAD SUITE 216 - SAN ANTONIO,TX 78217 USA ph: 210-698-5334 fax: - biaf@redchip.com http://www.bioaffinitytech.com

• General Corporate Information    Officers Maria Zannes - President; Chief Executive Officer; and Director Steven Girgenti - Executive Chairman and Director J. Michael Edwards - Chief Financial Officer Robert Anderson - Director Stuart Diamond - Director Peer Information bioAffinity Technologies, Inc. (CORR.) bioAffinity Technologies, Inc. (RSPI) bioAffinity Technologies, Inc. (CGXP) bioAffinity Technologies, Inc. (BGEN) bioAffinity Technologies, Inc. (GTBP) bioAffinity Technologies, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 09076W109 SIC: 8731 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/25 Next Expected EPS Date: 11/13/25 Share - Related Items Shares Outstanding: 28.47 Most Recent Split Date: (:1) Beta: 2.52 Market Capitalization: $7.69 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/13/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: - Price/Cash Flow: - Price / Sales: 1.00 EPS Growth vs. Year Ago Period: 31.58% vs. Previous Quarter: 18.75% Sales Growth vs. Year Ago Period: -47.04% vs. Previous Quarter: -31.50% ROE 06/30/25 - -845.68 03/31/25 - -367.64 12/31/24 - -253.63 ROA 06/30/25 - -181.92 03/31/25 - -154.15 12/31/24 - -131.63 Current Ratio 06/30/25 - 0.64 03/31/25 - 0.55 12/31/24 - 0.87 Quick Ratio 06/30/25 - 0.63 03/31/25 - 0.53 12/31/24 - 0.86 Operating Margin 06/30/25 - -138.32 03/31/25 - -110.53 12/31/24 - -97.62 Net Margin 06/30/25 - -152.16 03/31/25 - -110.53 12/31/24 - -97.62 Pre-Tax Margin 06/30/25 - -151.64 03/31/25 - -110.35 12/31/24 - -96.43 Book Value 06/30/25 - -0.08 03/31/25 - 0.08 12/31/24 - 0.17 Inventory Turnover 06/30/25 - 158.76 03/31/25 - 190.19 12/31/24 - 259.49 Debt-to-Equity 06/30/25 - - 03/31/25 - 0.27 12/31/24 - 0.18 Debt-to-Capital 06/30/25 - - 03/31/25 - 21.07 12/31/24 - 15.14

Powered by Zacks Investment Research ©